Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

End-user involvement in a systematic review of quantitative and qualitative research of non-pharmacological interventions for attention deficit hyperactivity disorder delivered in school settings: reflections on the impacts and challenges.

Coon JT, Gwernan-Jones R, Moore D, Richardson M, Shotton C, Pritchard W, Morris C, Stein K, Ford T.

Health Expect. 2016 Oct;19(5):1084-97. doi: 10.1111/hex.12400. Epub 2015 Sep 21.

2.

Hydrogen-borrowing and interrupted-hydrogen-borrowing reactions of ketones and methanol catalyzed by iridium.

Shen D, Poole DL, Shotton CC, Kornahrens AF, Healy MP, Donohoe TJ.

Angew Chem Int Ed Engl. 2015 Jan 26;54(5):1642-5. doi: 10.1002/anie.201410391. Epub 2014 Dec 9.

3.

Direct core functionalisation of naphthalenediimides by iridium catalysed C-H borylation.

Lyall CL, Shotton CC, Pérez-Salvia M, Pantoş GD, Lewis SE.

Chem Commun (Camb). 2014 Nov 18;50(89):13837-40. doi: 10.1039/c4cc06522k.

PMID:
25259375
4.
5.

The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.

Coley HM, Shotton CF, Kokkinos MI, Thomas H.

Gynecol Oncol. 2007 May;105(2):462-9. Epub 2007 Feb 14.

PMID:
17300833
6.

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.

Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H.

Biochem Pharmacol. 2006 Oct 16;72(8):941-8. Epub 2006 Aug 24.

PMID:
16934227
7.

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S.

Int J Cancer. 2003 Jun 10;105(2):273-80.

8.

CD4-dependent and CD4-independent HIV-2: consequences for neutralization.

Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A.

AIDS. 2003 Feb 14;17(3):291-300.

PMID:
12556682
9.

Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response.

Jeffs SA, Shotton C, Balfe P, McKeating JA.

J Gen Virol. 2002 Nov;83(Pt 11):2723-32.

PMID:
12388808
10.

Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein.

Flint M, Thomas JM, Maidens CM, Shotton C, Levy S, Barclay WS, McKeating JA.

J Virol. 1999 Aug;73(8):6782-90.

11.

Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA.

J Virol. 1999 Aug;73(8):6235-44.

12.

Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8.

Kellam P, Bourboulia D, Dupin N, Shotton C, Fisher C, Talbot S, Boshoff C, Weiss RA.

J Virol. 1999 Jun;73(6):5149-55.

13.

Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

McKnight A, Shotton C, Cordell J, Jones I, Simmons G, Clapham PR.

J Virol. 1996 Jul;70(7):4598-606.

14.

Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein.

McKeating JA, Shotton C, Jeffs S, Palmer C, Hammond A, Lewis J, Oliver K, May J, Balfe P.

Immunol Lett. 1996 Jun;51(1-2):101-5.

PMID:
8811352
15.

Change in tropism upon immune escape by human immunodeficiency virus.

McKnight A, Weiss RA, Shotton C, Takeuchi Y, Hoshino H, Clapham PR.

J Virol. 1995 May;69(5):3167-70.

16.

Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.

Wu Z, Kayman SC, Honnen W, Revesz K, Chen H, Vijh-Warrier S, Tilley SA, McKeating J, Shotton C, Pinter A.

J Virol. 1995 Apr;69(4):2271-8.

18.

Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, et al.

J Virol. 1993 Aug;67(8):4932-44.

Supplemental Content

Loading ...
Support Center